CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2006--Alkermes, Inc. (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live by JPMorgan on Tuesday, January 10, 2006 at 2:30 p.m. EST (11:30 a.m. PST). Richard Pops, CEO of Alkermes, will provide an overview of the company and review the company's corporate goals for 2006. The presentation will be webcast from the Westin St. Francis Hotel in San Francisco, California, and may be accessed under the investor relation's tab at www.alkermes.com. The presentation will be archived for 30 days.
Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, RISPERDAL(R) CONSTA(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson. The Company's lead proprietary product candidate, VIVITROL(TM) (naltrexone for extended-release injectable suspension), is being developed as a once-monthly injection for the treatment of alcohol dependence. The Company has a pipeline of extended-release injectable products and pulmonary drug products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.
CONTACT: Alkermes, Inc.
Debra Koufos, 617-583-6220
Associate, Corporate Communications
SOURCE: Alkermes, Inc.